<DOC>
	<DOCNO>NCT00871169</DOCNO>
	<brief_summary>This phase II trial study side effect well irinotecan hydrochloride , oxaliplatin cetuximab work treat patient unresectable metastatic pancreatic cancer . Irinotecan hydrochloride may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving irinotecan hydrochloride together oxaliplatin cetuximab may kill tumor cell .</brief_summary>
	<brief_title>Combination Irinotecan , Oxaliplatin Cetuximab Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>The investigator evaluate side effect well irinotecan hydrochloride , oxaliplatin cetuximab work treat patient unresectable metastatic pancreatic cancer . Irinotecan hydrochloride may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving irinotecan hydrochloride together oxaliplatin cetuximab may kill tumor cell .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . All patient , 18 year age old , histology proven pancreatic cancer eligible . 2 . Patients must life expectancy least 12 week . 3 . Patients must Zubrod performance status 02 . 4 . Patients must sign informed consent . 5 . Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; = 1,500 cells/mm3 platelet count &gt; = 60,000/mm3 absence regular red blood cell transfusion requirement . 6 . Patients adequate hepatic function total bilirubin &lt; = 4.0 mg/dl , could &lt; = 10 mg/ml biliary drainage tube place functional newly diagnose patient , SGOT SGPT &lt; = four time upper limit normal , adequate renal function define serum creatinine &lt; = 1.5 x upper limit normal . 7 . For patient treat one study medication allow long treatment contain 2 study medication time . For example , irinotecan capecitabine combination allow irinotecan cetuximab . Similarly , gemcitabine cetuximab allow gemcitabine , oxaliplatin cetuximab . Treated irinotecan alone follow oxaliplatin allow irinotecan combination oxaliplatin . 8 . Patients allow 2 prior treatment . The protocol also include chemotherapy na√Øve patient . 1 . Patients symptomatic brain metastasis exclude study . 2 . Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception . 3 . Patients may receive concurrent chemotherapy radiation therapy trial . 4 . Patients severe medical problem uncontrolled diabetes mellitus cardiovascular disease active infection eligible trial . 5 . Known hypersensitivity reaction study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Irinotecan</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Advanced metastatic pancreatic cancer</keyword>
</DOC>